Lymphocyte counts in patients with ANCA-associated vasculitis

被引:0
作者
Andreas Holbro
Philipp Schuetz
Christoph Berger
Christoph Hess
Thomas Daikeler
机构
[1] University Hospital Basel,Division of Hematology
[2] University Hospital Basel,Division of Endocrinology, Institute of Clinical Epidemiology
[3] University Hospital Basel,Department of Internal Medicine
[4] University Hospital Basel,Department of Rheumatology
来源
Rheumatology International | 2009年 / 29卷
关键词
Vasculitis; ANCA; Lymphocytes; AAV; Prognostic; Variability;
D O I
暂无
中图分类号
学科分类号
摘要
How lymphocyte counts relate to treatment-response in patients with ANCA-associated vasculitis (AAV) is controversial, and data on short-term variability of lymphocyte counts are lacking. Retrospective single center evaluation of disease activity and lymphocyte counts in patients with AAV, and of lymphocyte counts in kidney transplant-recipients, were done; both at the University Hospital Basel, Switzerland. Twenty-three patients with AAV were included. Remission was achieved in all patients. Ten patients experienced a relapse after a median of 66 weeks (range 15–189 weeks). Median lymphocyte counts at diagnosis were significantly higher than at remission (1.38 × 109/L vs. 0.99 × 109/L; P = 0.007). By contrast, median lymphocyte counts at remission and relapse did not differ significantly. However, intra-individual variability of lymphocyte counts early after diagnosis was high [median lymphocyte variability-range during the first 3 weeks of treatment 1.57 (range 0.27–3.95), n = 17]. This variability was not specific to patients with AAV, but was also observed in patients after kidney transplantation [variability of 1.76 (range 0.74–3.95, n = 31)]. The significantly higher median lymphocyte counts at diagnosis of AAV make lymphocyte counts a valuable surrogate for the treatment-efficiency in clinical studies. By contrast, on a patient-level, variability of lymphocyte counts impedes meaningful interpretation of individual measurements.
引用
收藏
页码:807 / 810
页数:3
相关论文
共 60 条
[1]  
Hoffman GS(1992)Wegener granulomatosis: an analysis of 158 patients Ann Intern Med 116 488-498
[2]  
Kerr GS(1996)Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis Ann Intern Med 124 477-484
[3]  
Leavitt RY(2007)Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis Curr Opin Rheumatol 19 17-24
[4]  
Hallahan CW(1994)T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener’s granulomatosis (WG) Clin Exp Immunol 98 448-453
[5]  
Lebovics RS(2006)Antineutrophil cytoplasmic antibodies Lancet 368 404-418
[6]  
Travis WD(2006)Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis 65 841-844
[7]  
Talar-Williams C(2007)Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience Medicine (Baltimore) 86 269-277
[8]  
Hijazi YM(2002)Lymphopenia in Wegener’s granulomatosis. A new clinical activity index? Nephron 92 466-471
[9]  
Walther MM(2006)Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual Arthritis Rheum 55 799-806
[10]  
Linehan WM(1990)The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction Arthritis Rheum 33 1065-1067